Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CPS1 | P31327 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30635270 | 0.89 | USP30 (0.45) | HIF1AUSP30MAPTNPC1RAB9A | |
| SCHEMBL24778719 | 0.86 | MAPT (0.45) | USP30USP2MAPTNPC1RAB9A | |
| SCHEMBL31315432 | 0.85 | HIF1A (0.46) | HIF1AUSP2MAPTALDH1A1 | |
| SCHEMBL31198887 | 0.84 | RARB (0.47) | HIF1AUSP30USP2RORCMALT1 | |
| SCHEMBL21876734 | 0.83 | PDE4D (0.38) | HIF1AUSP2RORCIP6K1MALT1 | |
| SCHEMBL31199021 | 0.81 | RARB (0.42) | USP30CHRM4MAPTALDH1A1 | |
| SCHEMBL20211889 | 0.80 | DPP4 (0.36) | HIF1AUSP30MAPTACACB | |
| SCHEMBL29683460 | 0.80 | DPP4 (0.36) | HIF1AUSP30MAPTACACB | |
| SCHEMBL31289261 | 0.79 | CCR1 (0.41) | MAPTNOTUMRAB9AACACB | |
| SCHEMBL7135104 | 0.79 | USP2 (0.63) | USP2MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| WO-2025087291-A1 | IRAK4 TARGETED DEGRADATION AGENT COMPOUND, AND USE THEREOF | 江苏先声药业有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119285638-A | Compounds that inhibit CDK2/4/6 activity | 斯迈旭(北京)生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119285639-A | CDK9 protein degradation targeting chimeras | 斯迈旭(北京)生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, TEC | HIF1A 4383/4885USP30 1361/4885TTR 3213/4885 |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, LYN | HIF1A 4287/4885USP30 1113/4885TTR 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.